Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Application of the Adenosine Triphosphate-based Response Assay in Intravesical Chemotherapy for Superficial Bladder Cancer

  • Ge, Wen-Qing (Department of Urinary Surgery, The First Affiliated hospital of Soochow University) ;
  • Pu, Jin-Xian (Department of Urinary Surgery, The First Affiliated hospital of Soochow University) ;
  • Zheng, Shi-Ying (Department of Thoracic Cardiac Surgery, The First Affiliated hospital of Soochow University)
  • Published : 2012.02.29
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To investigate correlations between adenosine triphosphate chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-based chemotherapy for drug selection in patients receiving intravesical chemotherapy to prevent recurrence of superficial bladder cancer after surgery. Methods: The chemosensitivities of 12 anticancer drugs were evaluated, including 5-Fu ADM, and EPI, using ATP-CRA and primary tumor cell culture in 54 patients. In addition, a further 58 patients were treated according to clinical experience. Differences in post-chemotherapeutical effects between drug sensitivity assay and experience groups were compared. Results: The evaluable rate of the test was 96.3%, the clinical effective rate was 80.8%, the sensitivity rate was 97.6% (41/42), the specificity was 20%, the total predicting accuracy was 74.3%, the positive predictive value was 83.7% (41/49), the negative predictive value was 66.7% (2/3); in the drug sensitivity test group, the clinical effective rate was 80.8%, the experience group response rate was 63.8%, with a significant difference in clinical effects between the ATP-based sensitivity and experience groups (${\chi}^2$=7.0153, P<0.01). Conclusion: ATP-CRA is a stable, accurate and potentially practical chemosensitivity test providing a predictor of chemotherapeutic response in patients with superficial bladder cancer.

Keywords

References

  1. Cree IA, Andreotti PE (1997). Measurement of cytotoxicity by ATP based luminescence assay in primary cell cultures and cell lines. Toxicol In Vitro, 11, 553-6. https://doi.org/10.1016/S0887-2333(97)00060-X
  2. Cree IA, Kurbacher CM (1997). Individualizing chemotherapy for solid tumors-is there any alternative? Anticancer Drugs, 8, 541-8. https://doi.org/10.1097/00001813-199707000-00001
  3. Cree IA, Kurbacher CM, Lamont A, et a1 (2007). A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs, 18, 1093-101. https://doi.org/10.1097/CAD.0b013e3281de727e
  4. Ekwall B, Sussman N (2000). ATP is the most accurate endpoint for in vitro predicting of cytotoxicity. ATLA, 28, 201-34.
  5. Garcia O, Massieu L (2003). Glutamate uptake inhibitor L-Transpyrrolidine 2, 4-dicarboxylate becomes neurotoxic in the presence of subthreshold concentrations of mitochondrial toxin 3-nitropropionate: involvement of mitochondrial reducing activity and ATP production. J Neurosci Res, 74, 956-66. https://doi.org/10.1002/jnr.10825
  6. Gasion JP, Cruz JF (2006). Improving Efficacy of Intravesical Chemotherapy. European Urology, 50, 225-34. https://doi.org/10.1016/j.eururo.2006.05.035
  7. Huh JW, Park YA, Lee KY, et al (2009). Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer-secondary publication. Yonsei Med, 50, 697-703. https://doi.org/10.3349/ymj.2009.50.5.697
  8. Jichlinski P, Guillou L, Karlsen SJ, et al (2003). Hexylaminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--A multicenter study. J Urol, 170, 226-9. https://doi.org/10.1097/01.ju.0000060782.52358.04
  9. Kangas L, Gronroos M, Nieminen AL (1984). Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol, 62, 338-43.
  10. Kornmann M, Beger HG, Link KH (2003). Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. Recent Results Cancer Res, 161, 180-95. https://doi.org/10.1007/978-3-642-19022-3_15
  11. Kurbacher CM, Grecu OM, Stier U, et al (2003). ATP chemosensitivity testing in ovarian and breast cancer:early clinical trials. Recent Results Cancer Res, 161, 221-30. https://doi.org/10.1007/978-3-642-19022-3_17
  12. Moon YW, Choi SH, Kim YT, et al (2007). Adenosine triphosphate-based chemotherapy response assay (ATPCRA)- guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer, 109, 1829.
  13. Mueller H, Kassack MU, Wiese M (2004). Comparison of the usefulness of the MTT,ATP and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J Biomol Screen, 9, 506-15. https://doi.org/10.1177/1087057104265386
  14. O'Meara AT, Sevin BU (2001). Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol, 83, 334-421. https://doi.org/10.1006/gyno.2001.6395
  15. Riedl CR, Daniltchenko D, Koenig F, et al (2001). Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrencen rate in superficial bladder cancer. J Urol, 165, 1121-3. https://doi.org/10.1016/S0022-5347(05)66442-7
  16. Schmittgen TD, Au JLS, Wientjes G, et a1 (1991). Cultured human bladder tumors for pharmacodynamic studies. Urology, 145, 203-7. https://doi.org/10.1016/S0022-5347(17)38292-7
  17. Serretta V, Galuffo A, Pavone C, et al (2005). Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology, 65, 65-9. https://doi.org/10.1016/j.urology.2004.08.027
  18. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al (2006). Predicting recurrence and progression in individual patients with stage Ta T1bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trial. Eur Urol, 49, 466-77. https://doi.org/10.1016/j.eururo.2005.12.031
  19. Ulukaya E, Ozdikicioglu F, Oral AY, et al (2008). The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicol In Vitro, 22, 232-9. https://doi.org/10.1016/j.tiv.2007.08.006
  20. Yamaue H, Tanimura H, Tsunoda T, et al (1991). Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur J Cancer, 27, 1258-63. https://doi.org/10.1016/0277-5379(91)90093-S

Cited by

  1. Sulforaphane Inhibits the Proliferation of the BIU87 Bladder Cancer Cell Line via IGFBP-3 Elevation vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1517